Adlai Nortye Ltd. American Depositary Shares
ANLDividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| August 29, 2008 | $0.25 | 2008-08-13 | 2008-08-15 |
| May 30, 2008 | $0.25 | 2008-05-14 | 2008-05-16 |
| February 29, 2008 | $0.25 | 2008-02-13 | 2008-02-15 |
| November 30, 2007 | $0.25 | 2007-11-14 | 2007-11-16 |
| August 31, 2007 | $0.25 | 2007-08-15 | 2007-08-17 |
Dividends Summary
- Consistent Payer: Adlai Nortye Ltd. American Depositary Shares has rewarded shareholders with 20 dividend payments over the past 5 years.
- Total Returned Value: Investors who held ANL shares during this period received a total of $5.00 per share in dividend income.
- Latest Payout: The most recent dividend of $0.25/share was paid 6532 days ago, on August 29, 2008.
- Yield & Schedule: ANL currently pays dividends quarterly with an annual yield of 8.67%.
- Dividend Growth: Since 2003, the dividend payout has grown by 0.0%, from $0.25 to $0.25.
- Dividend Reliability: ANL has maintained or increased its dividend for 20 consecutive payments.
Company News
Adlai Nortye Ltd. (Nasdaq: ANL), a clinical-stage biotechnology company, announced a $150 million private placement of 11.32 million ADSs at $13.25 per share. The oversubscribed offering attracted participation from new institutional investors including Soleus Capital, Perceptive Advisors, and ADAR1 Capital Management, as well as existing investo...
Adlai Nortye Ltd. announced that the first patient has been dosed in the United States in its Phase 1 clinical trial of AN9025, an oral pan-RAS(ON) inhibitor for advanced solid tumors with RAS mutations. The trial is being conducted as a multi-regional clinical trial in collaboration with Jiangsu Aosaikang Pharmaceutical Co. Ltd., with Adlai Nort...
Adlai Nortye, a clinical-stage biotechnology company, will participate in two healthcare investor conferences in late 2025 and early 2026, presenting its innovative cancer therapy pipeline.
Adlai Nortye will present research on AN4035, a novel CEACAM5-targeting antibody drug conjugate, at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston on October 25, 2025.
SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, May 23, 2024 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that it will present encouraging preliminary data of AN0025 in co...
